Search

Your search keyword '"Jørgensen, Jan Trøst"' showing total 168 results
Start Over Author "Jørgensen, Jan Trøst"
168 results on '"Jørgensen, Jan Trøst"'

6. Contributors

Author

Albesa, Roger, primary, Aure, Mary Ann, additional, Auza, Carolina, additional, Bizzaro, Nicola, additional, Bradbury, Joanne, additional, Choi, May Y., additional, Deane, Kevin D., additional, Fritzler, Marvin J., additional, Hirschfield, Gideon M., additional, Hudson, Marie, additional, Jørgensen, Jan Trøst, additional, Kubassova, Olga, additional, MacMartin-Moglia, Kim, additional, Mahler, Michael, additional, Martin, Lily W., additional, Martinez-Prat, Laura, additional, Melus, Carlos, additional, Mieli-Vergani, Giorgina, additional, Norman, Gary L., additional, Prisco, Lauren C., additional, Rossin, Brenden, additional, Satoh, Minoru, additional, Sciascia, Savino, additional, Shaikh, Faiq, additional, Sparks, Jeffrey A., additional, Vergani, Diego, additional, Villalta, Danilo, additional, and Wu, Jungen Andrew, additional

Published
2021
Full Text
View/download PDF

13. List of Contributors

Author

Alturkistani, Abrar, primary, An, Juanjuan, additional, Benda, Norbert, additional, Bienfait, Karina, additional, Blackler, Adele R., additional, Bøgsted, Martin, additional, Brindley, David, additional, Broich, Karl, additional, Brøndum, Rasmus F., additional, Brunhoeber, Patrick, additional, Bureau, Matthew, additional, Car, Josip, additional, Carter, Alison, additional, Clarke, Tara, additional, Clements, June, additional, Cross, Darren, additional, Doble, Brett, additional, Dolled-Filhart, Marisa, additional, Domazetoski, Elena, additional, Duncan, Mark W., additional, ElGabry, Ehab A., additional, Ellison, Aaron R., additional, Emancipator, Kenneth, additional, Enzmann, Harald, additional, Farooq, Maria, additional, Feng, Janine, additional, Foley, Kimberley, additional, Generalov, Evgenii, additional, Go, Ning Fei, additional, Goltsov, Alexey, additional, Green, George A., additional, Hersom, Maria, additional, Honarpour, Narimon, additional, Iddamalgoda, Lahiru, additional, Ikeda, Masayuki, additional, Jenkins, Suzanne, additional, Jørgensen, Jan Trøst, additional, Kapadia, Monesh, additional, Karwowska, Sylwia, additional, Kuzulugil, Sebnem S., additional, Lam, Ching, additional, Lewis, Jason S., additional, Li, Jinbo, additional, Liesenfeld, Oliver, additional, Lopes, Gilberto, additional, Luo, Dee, additional, Meinert, Edward, additional, Meyer, Ralf, additional, Mistry, Amita, additional, Mitsakakis, Nicholas, additional, Mollerup, Jens, additional, Montalto, Michael C., additional, Murata, Lauren B., additional, Murtaza, Muhammed, additional, Nielsen, Karsten Bork, additional, Pant, Saumya, additional, Parker, Jayson L., additional, Pereira, Patrícia M.R., additional, Ramarao, Manjunath, additional, Rigl, Ted, additional, Schildgen, Oliver, additional, Schildgen, Verena, additional, Scholl, Catharina, additional, Scudder, Sidney A., additional, Seyfried, Donna, additional, Sharma, Abha, additional, Shimazawa, Rumiko, additional, Simon, Richard, additional, Singh, Shalini, additional, Sobol, Nicholas B., additional, Stanforth, David A., additional, Stingl, Julia, additional, Sundararajan, Vijayaraghava Seshadri, additional, Suravajhala, Prashanth, additional, Tosolini, Alessandra, additional, Tsou, Jeff, additional, Tully, Kathryn M., additional, Walk, Eric E., additional, Wu, Dianna, additional, Xu, Xiaolei, additional, and Yu, Karen, additional

Published
2019
Full Text
View/download PDF

39. Site-agnostic biomarker-guided oncology drug development.

Author

Jørgensen, Jan Trøst

Abstract

Advances within molecular diagnostics have enabled us to identify a number of oncogenic drivers across different cancers. Many cancers can now be divided into subgroups based on molecular characteristics, and an increasing number of targeted anticancer drugs have been developed together with a predictive biomarker assay using the drug-diagnostic codevelopment model. With the recent approval of entrectinib, larotrectinib, and pembrolizumab for site-agnostic indications, biomarker-guided drug development has entered into a new phase. The review focuses on the general principles of drug-diagnostic codevelopment, especially basket trials and site-agnostic drug development. Special attention is paid to entrectinib, larotrectinib, and pembrolizumab. The recent approval of entrectinib, larotrectinib, and pembrolizumab must be regarded as a paradigm shift in biomarker-guided oncology drug development. For a site-agnostic indication, it is important to have in mind the central role of the companion diagnostic (CDx), as the assay defines the 'disease' and the patient population to be treated. A number of site-agnostic drugs are currently in development and here, it is important that CDx assay development is given high priority, so an analytical and clinical validated assay is available at the time of drug approval. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results